MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Quarterly Earnings Results

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09), Zacks reports.

MoonLake Immunotherapeutics Trading Down 0.0 %

Shares of MoonLake Immunotherapeutics stock traded down $0.01 during trading hours on Friday, hitting $41.76. 302,843 shares of the company were exchanged, compared to its average volume of 439,783. The business has a 50-day moving average of $46.49 and a 200-day moving average of $48.94. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $58.26. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -32.37 and a beta of 1.28.

Analysts Set New Price Targets

Several research firms have commented on MLTX. Wedbush reaffirmed an "outperform" rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. HC Wainwright reiterated a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a report on Thursday. The Goldman Sachs Group dropped their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday. Finally, Needham & Company LLC increased their price target on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a "buy" rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of "Buy" and an average target price of $83.20.

Remove Ads

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.